...
首页> 外文期刊>Journal of Medicinal Chemistry >Structure-Based Macrocycle Design in Small-Molecule Drug Discovery and Simple Metrics To Identify Opportunities for Macrocyclization of Small-Molecule Ligands
【24h】

Structure-Based Macrocycle Design in Small-Molecule Drug Discovery and Simple Metrics To Identify Opportunities for Macrocyclization of Small-Molecule Ligands

机译:小分子药物发现中基于结构的宏观整数设计和简单的指标,以确定小分子配体的宏核的机会

获取原文
获取原文并翻译 | 示例
           

摘要

Interest is growing in the use of macrocycles in pharmaceutical discovery. Macrocylization may provide a gateway to an expanded chemical space for small-molecule drug discovery, and this could be beneficial in prosecuting difficult targets, e.g., protein-protein interactions. Most, but not all, macrocycle drugs are derived from natural products. Studies on synthetic drug-like small-molecule macrocycles are limited, and our current understanding of macrocycle drugs is similarly limited. Following some background discussion, we review several examples of the structure-based design of synthetic macrocycles. Our opinion is that in conformationally suitable systems macrocycles are an analog class worthy of consideration. We then summarize an approach for the initial evaluation of molecules as candidates for macrocyclization.
机译:利息正在使用宏ycles在药物发现中的使用。 宏观化可以向扩大的化学空间提供用于小分子药物发现的通气孔,这可能是有益于起诉困难的靶标,例如蛋白质 - 蛋白质相互作用。 大多数但不是全部,宏细胞药物来自天然产物。 关于合成药物的小分子宏杂种的研究有限,我们目前对宏细胞药物的理解是类似的限制。 在一些背景讨论之后,我们审查了合成宏型基于结构的结构的几个例子。 我们认为,在综合合适的系统中,宏细是值得考虑的模拟类。 然后,我们总结了一种方法,以初步评估分子作为宏次数的候选者。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号